Literature DB >> 18043928

Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease.

Samantha Zak1, John Treven, Nolly Nash, Linda S Gutierrez.   

Abstract

BACKGROUND AND AIMS: Vascular abnormalities and expression of pro-angiogenic factors are observed in inflammatory bowel diseases (IBD). In this study, the role of thrombospondin-1 (TSP-1), an antiangiogenic protein, was analyzed using the dextran sulfate sodium (DSS) model for IBD.
MATERIALS AND METHODS: Wild-type (WT) and thrombospondin-1-deficient (TSP-1(-/-)) mice were subjected to four cycles (7 days) of DSS. Basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), transforming growth factor beta 1 (TGFbeta-1), and pro-apoptotic proteins such as Fas and its ligand (FasL) were determined by enzyme-linked immunosorbent assay. Double immunohistochemistry for cluster of differential 31 (CD31) and panendothelial cell antigen-32 antibodies was performed for detecting blood vessels. The terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay was also performed for identifying apoptotic cells. Inflammation, dysplasia, microvascular density (MVD), apoptotic indices (AI), protein 53 (p53), and beta-catenin expression were determined.
RESULTS: VEGF and bFGF protein levels and MVD were higher in the TSP-1(-/-) mice (p = 0.0312, p = 0.0246, and p = 0.0085, respectively). AI in the endothelial cells (EC) and FasL levels were significantly lower in TSP-1(-/-) compared to WT mice (p = 0.0042 and p = 0.0362, respectively). Dysplasia was detected in 66% of TSP-1(-/-) mice compared to 14% in WT mice. Hscores of ss-catenin and areas overexpressing p53 were higher in TSP-1(-/-) mice (p = 0.0002 and p = 0.0339, respectively).
CONCLUSION: TSP-1 may decrease angiogenesis by reducing the levels of pro-angiogenic factors and inducing apoptosis in EC through the Fas or FasL pathway. These findings, along with the increased overexpression of p53 and beta-catenin in TSP-1(-/-) mice, underline its role in carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18043928     DOI: 10.1007/s00384-007-0397-5

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  34 in total

1.  Interactions between CD47 and thrombospondin reduce inflammation.

Authors:  Laurence Lamy; Arnaud Foussat; Eric J Brown; Paul Bornstein; Michel Ticchioni; Alain Bernard
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

Review 2.  Epidemiology of inflammatory bowel disease: an update.

Authors:  M G Russel; R W Stockbrügger
Journal:  Scand J Gastroenterol       Date:  1996-05       Impact factor: 2.423

3.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Authors:  B Jiménez; O V Volpert; S E Crawford; M Febbraio; R L Silverstein; N Bouck
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1.

Authors:  L Zhou; J S Isenberg; Z Cao; D D Roberts
Journal:  Oncogene       Date:  2006-01-26       Impact factor: 9.867

Review 5.  Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models.

Authors:  Darren N Seril; Jie Liao; Guang-Yu Yang; Chung S Yang
Journal:  Carcinogenesis       Date:  2003-03       Impact factor: 4.944

Review 6.  Regulation of tumor angiogenesis by thrombospondin-1.

Authors:  Bin Ren; Karen O Yee; Jack Lawler; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2005-12-21

7.  Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation.

Authors:  H S Cooper; S Murthy; K Kido; H Yoshitake; A Flanigan
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

8.  Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease.

Authors:  Antonio Di Sabatino; Rachele Ciccocioppo; Elia Armellini; Raffaele Morera; Laura Ricevuti; Paolo Cazzola; Ilaria Fulle; Gino Roberto Corazza
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

9.  Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma.

Authors:  S Tsujitani; H Shirai; S Tatebe; K Sugamura; S Ohfuji; Y Gomyo; M Maeta; H Ito; N Kaibara
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

View more
  15 in total

1.  Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model.

Authors:  Linda S Gutierrez; Jun Ling; Derek Nye; Konstantina Papathomas; Catherine Dickinson
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

2.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

3.  Mice lacking functional CD95-ligand display reduced proliferation of the intestinal epithelium without gross homeostatic alterations.

Authors:  Kari Trumpi; Ernst J A Steller; Wendy W de Leng; Daniëlle A Raats; Isaäc J Nijman; Folkert H M Morsink; Inne H M Borel Rinkes; Onno Kranenburg
Journal:  Med Mol Morphol       Date:  2015-12-23       Impact factor: 2.309

Review 4.  Thrombospondin-1: multiple paths to inflammation.

Authors:  Zenaida Lopez-Dee; Kenneth Pidcock; Linda S Gutierrez
Journal:  Mediators Inflamm       Date:  2011-07-03       Impact factor: 4.711

5.  Thrombospondin-1 and VEGF in inflammatory bowel disease.

Authors:  Canan Alkim; Damlanur Sakiz; Huseyin Alkim; Ayten Livaoglu; Tulin Kendir; Huseyin Demirsoy; Levent Erdem; Nihat Akbayir; Mehmet Sokmen
Journal:  Libyan J Med       Date:  2012-01-30       Impact factor: 1.657

6.  Inhibition of intestinal adenoma formation in APC(Min/+) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta.

Authors:  Hui-Ping Liu; Zu-Hua Gao; Shu-Xiang Cui; De-Fu Sun; Yan Wang; Cui-Rong Zhao; Hong-Xiang Lou; Xian-Jun Qu
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

7.  Polysaccharide hydrogel combined with mesenchymal stem cells promotes the healing of corneal alkali burn in rats.

Authors:  Yifeng Ke; Yixiang Wu; Xuan Cui; Xun Liu; Min Yu; Chunbo Yang; Xiaorong Li
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 8.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

9.  The role of thrombospondin 1 on intestinal inflammation and carcinogenesis.

Authors:  Linda S Gutierrez
Journal:  Biomark Insights       Date:  2008

10.  Thrombospondin and VEGF-R: is there a correlation in inflammatory bowel disease?

Authors:  Jaroslaw Wejman; Michal Pyzlak; Dariusz Szukiewicz; Dorota Jarosz; Wieslaw Tarnowski; Grzegorz Szewczyk
Journal:  Mediators Inflamm       Date:  2013-07-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.